Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "approval"

2612 News Found

Glenmark receives ANDA approval for Clindamycin Phosphate Gel
News | February 12, 2021

Glenmark receives ANDA approval for Clindamycin Phosphate Gel

According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.


Lupin receives approval for tavaborole topical solution
News | February 10, 2021

Lupin receives approval for tavaborole topical solution

Tavaborole Topical Solution, 5%, is an oxaborole antifungal.


Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities
News | January 26, 2021

Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities

Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business


Dr. Reddy’s gets approval for Sputnik V Phase 3 trial
News | January 16, 2021

Dr. Reddy’s gets approval for Sputnik V Phase 3 trial

The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.


Dr. Reddy’s seeks approval to continue Phase 3 trial
News | January 13, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial

The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.


HealthTech future will be defined by partnerships grounded in trust: Dr. Sabine Kapasi, CEO, Enira Consulting and Founder of ROPAN Healthcare
Opinion | May 26, 2026

HealthTech future will be defined by partnerships grounded in trust: Dr. Sabine Kapasi, CEO, Enira Consulting and Founder of ROPAN Healthcare

India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time


China greenlights Boehringer Ingelheim’s HERNEXEOS for aggressive lung cancer
Drug Approval | May 26, 2026

China greenlights Boehringer Ingelheim’s HERNEXEOS for aggressive lung cancer

The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer


Datroway wins US nod in aggressive breast cancer subtype
Drug Approval | May 25, 2026

Datroway wins US nod in aggressive breast cancer subtype

Clearance marks major shift beyond chemotherapy